Legend Biotech Corporation closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell cell therapies targeting Delta-like ligand protein 3, including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102.1 Under the terms of the license agreement closed , Legend Biotech will receive a $100 million upfront cash payment.
January 3, 2024
· 1 min read